Neuronetics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Neuronetics Inc 公司

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

Neuronetics Inc简介



公司代码STIM

公司名称Neuronetics Inc

上市日期Jun 28, 2018

CEOMr. Keith J. Sullivan

员工数量716

证券类型Ordinary Share

年结日Jun 28

公司地址3222 Phoenixville Pike

城市MALVERN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编19355

电话18776007555

网址https://neurostar.com/neuronetics/

公司代码STIM

上市日期Jun 28, 2018

CEOMr. Keith J. Sullivan

Neuronetics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Sasha Cucuz

Director

2.03M

+6410.00%

Mr. Robert A. (Rob) Cascella

Independent Non-Executive Chairman of the Board

588.77K

+10531.00%

Mr. Steven Pfanstiel

Chief Financial Officer, Executive Vice President, Treasurer

570.21K

+170212.00%

Mr. Glenn P. Muir

Independent Director

335.45K

+7554.00%

Ms. Sheryl L. Conley

Independent Director

185.35K

+7326.00%

Ms. Megan Rosengarten

Independent Director

140.89K

+30000.00%

Mr. Mark Klausner

Managing Partner

--

Mr. W. Andrew Macan

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

--

Dr. Avinash N. Amin, M.D.

Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Sasha Cucuz

Director

2.03M

+6410.00%

Mr. Robert A. (Rob) Cascella

Independent Non-Executive Chairman of the Board

588.77K

+10531.00%

Mr. Steven Pfanstiel

Chief Financial Officer, Executive Vice President, Treasurer

570.21K

+170212.00%

Mr. Glenn P. Muir

Independent Director

335.45K

+7554.00%

Ms. Sheryl L. Conley

Independent Director

185.35K

+7326.00%

Ms. Megan Rosengarten

Independent Director

140.89K

+30000.00%

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Clinic revenue

21.81M

58.47%

Treatment sessions

10.76M

28.84%

NeuroStar Advanced Therapy System

3.96M

10.61%

Other

776.00K

2.08%

地区USD

名称

营收

占比

United States

36.25M

97.19%

International

1.05M

2.81%

业务

地区

业务USD

名称

营收

占比

Clinic revenue

21.81M

58.47%

Treatment sessions

10.76M

28.84%

NeuroStar Advanced Therapy System

3.96M

10.61%

Other

776.00K

2.08%

股东统计

更新时间: 1月2日周五

持股股东

股东类型

持股股东

占比

Madryn Asset Management, LP

30.28%

Chernett (Jorey)

9.97%

UBS Financial Services, Inc.

3.81%

The Vanguard Group, Inc.

3.77%

BlackRock Institutional Trust Company, N.A.

3.10%

其他

49.08%

持股股东

占比

Madryn Asset Management, LP

30.28%

Chernett (Jorey)

9.97%

UBS Financial Services, Inc.

3.81%

The Vanguard Group, Inc.

3.77%

BlackRock Institutional Trust Company, N.A.

3.10%

其他

49.08%

股东类型

持股股东

占比

Private Equity

30.28%

Individual Investor

19.61%

Investment Advisor

13.93%

Hedge Fund

9.59%

Investment Advisor/Hedge Fund

6.14%

Research Firm

1.71%

Bank and Trust

0.10%

Pension Fund

0.05%

Venture Capital

0.04%

其他

18.55%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

216

42.35M

61.84%

-15.92M

2025Q3

198

39.45M

57.60%

-13.65M

2025Q2

187

47.56M

71.93%

-4.03M

2025Q1

191

47.19M

71.70%

-4.84M

2024Q4

155

36.70M

70.38%

+11.74M

2024Q3

153

14.58M

47.42%

-9.85M

2024Q2

159

20.22M

66.61%

-5.87M

2024Q1

183

20.38M

68.24%

-3.49M

2023Q4

191

18.37M

63.28%

-7.87M

2023Q3

201

19.69M

68.24%

-8.69M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Madryn Asset Management, LP

20.74M

30.28%

-3.50M

-14.44%

Aug 08, 2025

Chernett (Jorey)

4.40M

6.43%

+4.40M

--

Nov 17, 2025

UBS Financial Services, Inc.

2.16M

3.16%

+1.85M

+580.70%

Sep 30, 2025

The Vanguard Group, Inc.

2.83M

4.14%

+89.50K

+3.26%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

2.12M

3.1%

+75.30K

+3.68%

Sep 30, 2025

Cucuz (Sasha)

2.03M

2.97%

+6.41K

+0.32%

Oct 20, 2025

Balyasny Asset Management LP

1.82M

2.66%

+312.55K

+20.71%

Sep 30, 2025

Sullivan (Keith J)

1.61M

2.35%

--

Mar 24, 2025

Wexford Capital LP

1.18M

1.72%

+534.15K

+83.06%

Sep 30, 2025

Masters Capital Management, L.L.C.

1.00M

1.46%

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

AdvisorShares Psychedelics ETF

3.31%

Invesco NASDAQ Future Gen 200 ETF

0.43%

iShares Neuroscience and Healthcare ETF

0.1%

Vanguard US Momentum Factor ETF

0.04%

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

0.01%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.01%

Avantis US Small Cap Equity ETF

0%

ProShares Hedge Replication ETF

0%

Proshares Ultra Russell 2000

0%

AdvisorShares Psychedelics ETF

占比3.31%

Invesco NASDAQ Future Gen 200 ETF

占比0.43%

iShares Neuroscience and Healthcare ETF

占比0.1%

Vanguard US Momentum Factor ETF

占比0.04%

iShares Micro-Cap ETF

占比0.02%

iShares Russell 2000 Growth ETF

占比0.01%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.01%

Avantis US Small Cap Equity ETF

占比0%

ProShares Hedge Replication ETF

占比0%

Proshares Ultra Russell 2000

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据